Browse by author
Lookup NU author(s): Professor Luke ValeORCiD,
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Catheter-associated urinary tract infection (CAUTI) is the second most common cause of hospital-acquired infection. A number of strategies have been put forward to prevent CAUTI, including the use of antimicrobial catheters. We aimed to assess whether the use of either a nitrofurazone-impregnated or a silver alloy-coated catheter was cost-effective compared with standard polytetrafluoroethylene (PTFE)-coated catheters. A decision-analytic model using data from a clinical trial conducted in the United Kingdom was used to calculate the incremental cost per quality-adjusted life-year (QALY). We assumed that differences in costs and QALYs were driven by difference in risk of acquiring a CAUTI. Routine use of nitrofurazone-impregnated catheters was, on average, 7 pound ((sic)9) less costly than use of the standard catheter over 6 wk. There was a >70% chance that use of nitrofurazone catheters would be cost saving and an 84% chance that the incremental cost per QALY would be less than 30 pound 000 ((sic)36 851; a commonly used threshold for society's willingness to pay). Silver alloy-coated catheters were very unlikely to be cost-effective. The model's prediction, although associated with uncertainty, was that nitrofurazone-impregnated catheters may be cost-effective in the UK National Health System or a similar setting. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Author(s): Kilonzo M, Vale L, Pickard R, Lam T, N'Dow J, for the Catheter Trial Group
Publication type: Article
Publication status: Published
Journal: European Urology
Print publication date: 01/10/2014
Online publication date: 21/06/2014
Acceptance date: 27/05/2014
ISSN (print): 0302-2838
ISSN (electronic): 1873-7560
Publisher: Elsevier BV
Altmetrics provided by Altmetric